<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns2:studies xmlns:ns2="http://webservice.caaers.cabig.nci.nih.gov">
    <ns2:study>
        <shortTitle>A Phase 1 Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients</shortTitle>
        <longTitle>A Phase 1 Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients</longTitle>
        <description>A Phase 1 Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients</description>
        <phaseCode>Phase I Trial</phaseCode>
        <status>Active - Trial is open to accrual</status>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <adeersReporting>true</adeersReporting>
        <ns2:aeTerminology>
            <ns2:ctcVersion>
                <name>4</name>
            </ns2:ctcVersion>
        </ns2:aeTerminology>
        <ns2:diseaseTerminology>
            <diseaseCodeTerm>CTEP</diseaseCodeTerm>
        </ns2:diseaseTerminology>
        <drugAdministrationTherapyType>true</drugAdministrationTherapyType>
        <deviceTherapyType>false</deviceTherapyType>
        <radiationTherapyType>false</radiationTherapyType>
        <surgeryTherapyType>false</surgeryTherapyType>
        <behavioralTherapyType>false</behavioralTherapyType>
        <biologicalTherapyType>false</biologicalTherapyType>
        <geneticTherapyType>false</geneticTherapyType>
        <dietarySupplementTherapyType>false</dietarySupplementTherapyType>
        <otherTherapyType>false</otherTherapyType>
        <reportTypeCaaersXML>true</reportTypeCaaersXML>
        <reportTypeAdeersPDF>true</reportTypeAdeersPDF>
        <reportTypeMedwatchPDF>false</reportTypeMedwatchPDF>
        <reportTypeDCPSAEForm>false</reportTypeDCPSAEForm>
        <reportTypeCIOMSForm>false</reportTypeCIOMSForm>
        <reportTypeCIOMSAEForm>false</reportTypeCIOMSAEForm>
        <fundingSponsor>
            <organizationAssignedIdentifier>
                <value>7380</value>
            </organizationAssignedIdentifier>
            <ns2:studyFundingSponsor>
                <ns2:organization>
                    <name>Cancer Therapy Evaluation Program</name>
                    <nciInstituteCode>CTEP</nciInstituteCode>
                </ns2:organization>
            </ns2:studyFundingSponsor>
        </fundingSponsor>
        <coordinatingCenter>
            <organizationAssignedIdentifier>
                <value>MC0513</value>
            </organizationAssignedIdentifier>
            <ns2:studyCoordinatingCenter>
                <ns2:organization>
                    <name>Mayo Clinic Rochester</name>
                    <nciInstituteCode>MN026</nciInstituteCode>
                </ns2:organization>
            </ns2:studyCoordinatingCenter>
        </coordinatingCenter>
        <studyOrganizations>
            <ns2:studySite>
                <ns2:organization>
                    <name>Mayo Clinic Rochester</name>
                    <nciInstituteCode>MN026</nciInstituteCode>
                </ns2:organization>
            </ns2:studySite>
            <ns2:studySite>
                <ns2:organization>
                    <name>Wake Forest University Health Sciences</name>
                    <nciInstituteCode>NC002</nciInstituteCode>
                </ns2:organization>
            </ns2:studySite>
        </studyOrganizations>
        <identifiers/>
        <treatmentAssignments>
            <ns2:treatmentAssignment>
                <code>-1</code>
                <description>Cycle = 28 days: AFP464: 7mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>-2</code>
                <description>Cycle = 28 days: AFP464: 5mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>1</code>
                <description>Cycle = 28 days: AFP464: 10mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>10</code>
                <description>Cycle = 28 days: AFP464: 201mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>2</code>
                <description>Cycle = 28 days: AFP464: 14mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>3</code>
                <description>Cycle = 28 days: AFP464: 19mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>4</code>
                <description>Cycle = 28 days: AFP464: 27mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>5</code>
                <description>Cycle = 28 days: AFP464: 38mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>6</code>
                <description>Cycle = 28 days: AFP464: 53mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>7</code>
                <description>Cycle = 28 days: AFP464: 74mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>8</code>
                <description>Cycle = 28 days: AFP464: 103mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>9</code>
                <description>Cycle = 28 days: AFP464: 144mg/m2 IV over 3 hrs on days 1, 8, and 15</description>
            </ns2:treatmentAssignment>
        </treatmentAssignments>
        <studyAgents>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>AFP464 (aminoflavone prodrug)</name>
                </ns2:agent>
                <indType>CTEP_IND</indType>
                <partOfLeadIND>true</partOfLeadIND>
                <studyAgentINDAssociations>
                    <ns2:studyAgentINDAssociation>
                        <ns2:investigationalNewDrug>
                            <indNumber>-111</indNumber>
                        </ns2:investigationalNewDrug>
                    </ns2:studyAgentINDAssociation>
                </studyAgentINDAssociations>
            </ns2:studyAgent>
        </studyAgents>
        <ctepStudyDiseases>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Solid tumor, NOS</term>
                </ns2:diseaseTerm>
                <leadDisease>true</leadDisease>
            </ns2:ctepStudyDisease>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Hematopoietic malignancy, NOS</term>
                </ns2:diseaseTerm>
                <leadDisease>false</leadDisease>
            </ns2:ctepStudyDisease>
        </ctepStudyDiseases>
        <evaluationPeriods>
            <ns2:evaluationPeriod>
                <name>Baseline</name>
                <epochOrder>0</epochOrder>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Treatment</name>
                <epochOrder>1</epochOrder>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Post-treatment</name>
                <epochOrder>2</epochOrder>
            </ns2:evaluationPeriod>
        </evaluationPeriods>
        <expectedAECtcTerms>
            <ns2:expectedAECtcTerm>
                <ctepCode>10021425</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10016256</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10016558</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10002646</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10028813</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10047700</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10001675</ctepCode>
            </ns2:expectedAECtcTerm>
        </expectedAECtcTerms>
    </ns2:study>
</ns2:studies>
